Proteasome inhibition has recently been demonstrated to inhibit hepatic fibrogenesis in the BDL mouse by blocking stellate cell NF-AB activation. The effect of proteasome inhibition on liver injury, however, is unclear. Our current aims were to assess the effect of the proteasome inhibitor, bortezomib, on liver injury in the BDL mouse. Liver injury was assessed in 7-day BDL mice treated with a single dose of bortezomib on day 4 after bile duct ligation. Despite NF-AB inhibition by bortezomib, liver injury and hepatocyte apoptosis were reduced in treated BDL mice. The anti-apoptotic effect of bortezomib was likely mediated by an increase in hepatic c-FLIP levels, a potent anti-apoptotic protein. Unexpectedly, numerous mitotic hepatocytes were observed in the bortezomib treated BDL mice liver specimens.
INTRODUCTION
Cholestasis, defined as an impairment in bile formation, is a common occurrence in human liver diseases, and results in progressive liver injury culminating in cirrhosis and liver failure. Unfortunately, the therapeutic options for treating this syndrome remain limited, in part, because the essential mechanisms mediating cholestatic liver injury remain incompletely understood. The cellular complexity of liver injury in cholestatic syndromes is highlighted by the role of the transcription factor NF-AB. Elevated concentrations of bile acids within the hepatocyte during cholestasis activate NF-AB (28). NF-B induces cytoprotective gene expression in hepatocytes attenuating liver injury (21) . The innate immune system also contributes to cholestatic liver injury with Kupffer cell activation and neutrophil infiltration (5, 17) . Kupffer cell activation occurs by a NF-AB-dependent process (30, 36) ; in this context, NF-AB activation by promoting expression of death ligands by Kupffer cells (i.e. Fas ligand and TNF-E) is cytotoxic to the liver (8, 30) . Finally, stellate cell activation is responsible for the fibrosis which occurs in cholestasis (7) . NF-AB activation is a pivotal feature of stellate cell activation (19), and inhibition of NF-AB activation in stellate cells induces their apoptosis diminishing hepatic fibrosis (2, 10) . Thus, the global impact of inhibiting NF-AB pharmacologically on cholestatic liver injury remains unclear. On one hand, blocking NF-AB activation maybe expected to exacerbate liver injury by promoting hepatocytes damage. On the other hand, by inhibiting Kupffer cell and stellate cell activation blocking NF-AB activation would be expected to reduce liver injury.
NF-AB is normally complexed to an endogenous inhibitor protein I-AB in the cytosol (21) . NF-AB activating stimuli result in phosphorylation of I-AB leading to its dissociation from NF-AB and degradation by the proteasome (21) . Freed from the inhibitor protein, NFPage 3 of 32 
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AB translocates to the nucleus where it functions as a potent transcription factor. Proteasome inhibition, prevents I-AB degradation, thereby, keeping NF-AB complexed to this inhibitory protein despites its phosphorylation (35) . Thus, proteasome inhibitors, which are already available in clinical practice, are potential drugs to modulate NF-AB activation in liver diseases. Indeed, we have recently demonstrated that proteasome inhibitors will attenuate hepatic fibrogenesis in the bile duct ligated mouse by blocking NF-AB activation in stellate cells (2) . However, the composite effect of inhibiting NF-AB on liver injury was not assessed in these studies; in particular the effects on hepatocyte injury and Kupffer cell activation.
The overall objective of this study was to examine the effect of proteasome inhibition on liver injury in the bile duct ligated mouse. To address this objective we formulated two questions: i) What is the effect of proteasome inhibition on indices of hepatocytes injury; and ii) What is the effect of proteasome inhibition on Kupffer cell/macrophage activation. The results indicate that the proteasome inhibitor bortezomib reduces hepatocyte injury in the bile duct ligated mouse. Not only did this proteasome inhibitor reduce markers of Kupffer cell activation, but it also unexpectedly enhanced hepatocyte proliferation. Proteasome inhibition appears to be an attractive therapeutic strategy for cholestatic liver diseases
MATERIALS AND METHODS

Bile Duct Ligated Mouse Model of Liver Fibrosis
The use and the care of the animals were reviewed and approved by the Institutional Animal Care and Use Committee at the Mayo Clinic. C57/BL6 mice, 6 to 8 weeks of age, were used for these studies. Common bile duct ligation was performed as described by us in detail previously (29) . Bortezomib (Mayo Clinic Formulary, Rochester, MN) was administered at 0.1 mg/kg body wt by intraperitoneal injection (i.p.) on day 4 after BDL. Bortezomib was dissolved in saline as a vehicle, and control animals received saline alone. On day 7 after BDL, animals were sacrificed and serum and liver samples were removed for analysis.
Serum Assays
Under deep anesthesia, blood samples were collected after 7 days of BDL. Serum bilirubin and alanine aminotransferase (ALT) determinations were performed using commercially available assay kits following the manufacturer's instructions (Sigma Diagnostics kit; Sigma-Aldrich, St. Louis, MO). Serum TNF-levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Inc., Minneapolis, MN). Germany). Digital pictures were captured through a video archival system using a digital TV camera system (Axiocam High Resolution color, Carl Zeiss, Inc. Oberkochen, Germany).
Histological Analysis and TUNEL Assay
With an automated software analysis program (KS400, Zeiss, Inc. Oberkochen, Germany), the percent immunostained/field area of digital photomicrographs were quantified (38) . H&E stained slides of liver tissue specimens from BDL mice with or without Bortezomib treatment were analyzed for bile infarcts. Bile infracted areas (the percent infarct/field area) were also quantitated using digital image analysis technology.
Immunoblot Analysis Cellular extracts of whole mouse liver was prepared and
Western blot analysis was performed as described previously (1, 12) . For Western analysis, 50 µg of protein extract per lane was added to an equal volume of 2x sample buffer and was size-fractionated on 12 or 15% SDS-PAGE, transferred to nitrocellulose, and detected using Samples were separated on 5% polyacrylamide gels in 1X Tris-Borate EDTA (TBE) buffer (130 mM Tris, pH 8.3, 45 mM boric acid, 2.5 mM EDTA). Imaging was performed in the gel cassette on the Odyssey Infrared Imaging System (Li-cor Biosciences, Lincoln NE). An EMSA performed in this manner yields a gel with an appearance dissimiliar from an EMSA performed with radioactivity. The precast acrylamide gels have well markers attached to the glass, and these are apparent in the figure as vertical lines outlining the well. Also, as the oligonucleotide is labeled with a fluorescent probe, there is a moiety available for nonspecific binding to cellular proteins or large complexes.
Kupffer Cell Isolation Kupffer cells were isolated from bile duct ligated and sham operated mice. Kupffer cells were isolated by in situ digestion and cell separation on a discontinuous gradient of arabinogalactan (Larcoll; Sigma chemicals, St. Louis, MO), followed by selective adherence on glass cover-slips as described previously by Souto et al (33) , and Friedman and Roll (13) . The viability of isolated Kupffer cells was >90% as assessed by trypan blue exclusion. Cell lysates from Kupffer cells were obtained after 24-hour plating. Kupffer cells were cultured in Dulbecco's minimal essential medium (DMEM; Gibco-Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml gentamycin, and 100 nmol/L insulin. Data Analysis All data represent at least 3 independent experiments and are expressed as the mean ± S.E. unless otherwise indicated. Differences between groups were compared using 2-way ANOVA and a post hoc Bonferroni test to correct for multiple comparisons.
Real-Time-Polymerase Chain Reaction (PCR)
RESULTS
Bortezomib Blocks Hepatocyte NF-B Activation in BDL Mice
To examine the effects of bortezomib on hepatocytes in cholestasis, sham operated and 7-day BDL mice were treated with or without bortezomib on day 4 after the initial surgical procedure. On day 7 after surgery, the animals were sacrificed. Immunohistochemistry examination of liver specimens demonstrated NF-B p65 subunit immunoreactivity predominantly in nuclei of hepatocytes following BDL. In contrast, immunoreactivity for NF-B was excluded from the nucleus and localized to the cytoplasm in sham operated animals, animals treated with bortezomib, and in BDL mice receiving bortezomib (Fig. 1A) . In experiments complimentary to the p65 NF-B immunohistochemistry, we also examined p65 NF-B binding activity using a commercial ELISA-like assay. p65 NF-B binding activity in nuclear extracts was significantly reduced in bortezomib treated BDL mice as compared to nuclear extracts from untreated BDL animals (p<0.01) (Fig. 1B) . We also assessed NF-AB activation in the BDL mouse liver by EMSA (Fig.   1C ). The EMSA demonstrated that the nuclear protein extracts from the livers of BDL mice contained NF-AB capable of binding a fluorescent oligonucleotide including the NF-AB consensus binding motif. Nuclear extracts from sham-operated mice or bortezomib treated BDL mice did notbind the NF-AB consensus binding motif in this EMSA. To further assess the ability of this route, dose and timing of bortezomib administration to inhibit NF-AB activation, we measured the transcripts of two NF-AB target genes, iNOS (inducible type nitric oxide synthase) and the anti-apoptotic protein A1 ( Fig. 1D and E) . Consistent with the immunohistochemistry, ELISA and EMSA analysis, iNOS and A1 mRNA expression were significantly reduced in bortezomib treated as compared to untreated BDL mice (p<0.03 for iNOS; p<0.05 for A1). Thus, this route, dose and timing of bortezomib administration were sufficient, to at least partially, block hepatic NF-B activation.
Bortezomib Attenuates Liver Injury Following BDL Liver injury was examined by
measuring serum ALT concentrations. Serum ALT values were markedly increased in BDL mice as anticipated ( Fig. 2A) . However, serum ALT values were significantly reduced in bortezomib-treated BDL mice as compared with untreated BDL mice (328 ± 129 vs. 898 ± 400 U/L, respectively, p<0.05). Furthermore, bortezomib treatment following BDL reduced the number of TUNEL positive hepatocyte as compared to untreated BDL mice (5.6 ± 1.2 and 23.4 ± 4.7, respectively P<0.01) (Fig. 2B ). Bile infarcts are confluent foci of hepatocyte feathery degeneration due to bile acid cytotoxicity, and are a prominent feature of liver injury in the BDL mouse. Bile infarcts in the liver were assessed by conventional H&E staining and quantitated using digital image analysis. Histopathologic examination of liver specimens demonstrated numerous bile infarcts in untreated BDL mice. However, bortezomib treatment significantly reduced bile infarcts in the BDL mice ( Fig. 2 C, D) . The reduction in liver injury by bortezomib could not be explained by a change in cholestasis, as serum bilirubin values were not reduced by bortezomib treatment (Fig. 2E ). These data suggest that bortezomib attenuates hepatic injury in the BDL mice.
Recently, Chang and co-workers have demonstrated that proteasome inhibition blocks liver injury by concanavalin A by enhancing cellular c-FLIP levels, a potent inhibitor of death receptor signaling (9) . Indeed, c-FLIP was cytoprotective in these studies despite NF-B inhibition. Based on these very recent observations, we also examined c-FLIP expression in BDL mice. Indeed, bortezomib markedly enhanced hepatic c-FLIP protein levels in this model (Fig. 3A) . Consistent with the effect of a post translational effect of bortezomib as c- (Fig. 4C) . Taken together, these findings suggest that bortezomib administration to the BDL-mouse enhances hepatocytes proliferation.
Bortezomib Reduces Macrophage Number and Activation in the BDL Mice
Kupffer cells, resident macrophages of the liver, and likely additional macrophage recruited to the liver, contribute to cholestatic liver injury (22, 33, 37 (Fig. 5A, B) . As Kupffer cells and likely recruited macrophages are a major source of pro-inflammatory cytokines and chemokines during liver inflammation (3), serum TNF-levels were determined by an ELISA assay. Circulating serum TNFlevels were found to be decreased in bortezomib-treated mice compared with BDL-untreated mice (30.59 ± 4.47 vs. 78.79 ± 21.14 pg/ml, respectively, p<0.05) (Fig. 6A ). To more directly assess hepatic macrophage activity, this liver cells population was isolated from livers and mRNA extracted (Fig. 6B, C) . Indeed, hepatic macrophage, TNF-and Fas-L mRNA expression was also reduced in bortezomib treated and untreated animals (Fig. 6B, C) . Taken together, these data suggest that bortezomib therapy is associated with reduced hepatic macrophage activity in BDL mice.
DISCUSSION
The principal findings of this study relate to the potential therapeutic and/or deleterious effects of proteasome inhibition on cholestatic liver injury. We have previously demonstrated that proteasome inhibition attenuates fibrosis in this model by inducing stellate cell apoptosis. Therefore, this study focused on the effects of proteasome inhibition in hepatocytes and Kupffer cells/hepatic macrophages. The data indicate that administration of the proteasome inhibitor bortezomib to BDL mice: i) reduces hepatocyte apoptosis and liver injury; ii) enhances hepatocyte proliferation; and iii) reduces hepatic macrophage number and activation. These data suggest proteasome inhibition may be a new and unexpected therapeutic strategy for the treatment of cholestatic syndromes.
NF-AB is activated in BDL mice (4), presumably by bile acids (32) , and hepatocyte specific NF-AB inhibition exacerbates cholestatic liver injury in this model (28).
Unexpectedly, proteasome inhibition, which prevents NF-AB activation, actually reduced cholestatic liver injury in the current studies. Indeed, treatment of BDL mice with bortezomib reduced hepatocyte apoptosis and all indices of hepatic damage examined ( Fig. 1 and 2 ).
Karin and co-workers have recently demonstrated that proteasome inhibition also reduces liver injury by concanavalin A (9). In their studies, proteasome inhibition prevented loss of c-FLIP a potent inhibitor of death receptor mediated apoptosis (24) . We also observed an increase of hepatic c-FLIP following administration of bortezomib in BDL mice (Fig. 3) .
Several studies indicate that liver injury in the BDL mouse is mediated by the death receptor Fas (7, 18, 29) . Proteasome inhibition may be a pharmacologic approach to block death receptor signaling in the BDL-mouse liver by increasing hepatic c-FLIP. The beneficial effects of bortezomib in this model are likely not all related to reducing NF-AB activation.
Proteasome inhibition affects many cellular processes, and it is plausible that many cellular mechanisms account for the composite cytoprotection observed in these acute studies.
An 
